Author

Stefano Colloca

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1 Organism:rat· 1 Approach:statistical model· 1

Frequent Co-Authors

Angelo RaggioliiD· 2 shared Antonella FolgoriiD· 2 shared Michela Gentile· 2 shared Stefania CaponeiD· 2 shared Tariro MakadzangeiD· 2 shared Alessia Noto· 1 shared Alex SigaliD· 1 shared Alexandra Rogue· 1 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Angelo RaggioliORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Low seroprevalence of neutralizing antibodies to gorilla adenovirus 32 (GRAd32) in southern African populations supports evaluation of this vector platform for HIV vaccine development

Nonhlanhla N. Mkhize, Anna patjane, Nomcebo Shusha, Ashleigh Welsh, Tandile Hermanus, Prudence Kgagudi, Thopisang P. Motlou, Linda‐Gail Bekker, Glenda Gray, Nigel Garrett, Lee Fairlie, Alex Sigal, Wendy A. Burgers, Takudzwa Mangwaku, Tariro Makadzange, , Penny L. Moore

This study finds low neutralizing antibody prevalence to GRAd32 in southern African populations, suggesting its potential as an HIV vaccine vector despite prior Ad26 vaccination.

bioRxiv · May 26, 2026 · PreprintImmunology

A novel Gorilla-derived oncolytic Adenovirus with natural selective replication in cancer cells

Romina Scala, Ilaria Cela, Emily Capone, Valentina Proganò, Angiolo Pierantoni, Stefano Colloca, Gianluca Sala, Angelo Raggioli

This paper develops a novel gorilla-derived oncolytic adenovirus, GRAd32Fk25, which selectively replicates in tumor cells and expresses a therapeutic antibody, showing potential as an improved virotherapy compared to HAd5.

bioRxiv · Mar 1, 2026 · PreprintCancer Biology

Non-clinical safety of GRAd vector-based COVID-19 and HIV vaccines supports a platform regulatory approach

Reji Paalangara, Stéphanie Gohin, Alexis Menard, Charlotte Amy, Wahiba Berrabah, Alexandra Rogue, Matthew A. Getz, Aljawharah Alrubayyi, Simone Battella, Angelo Raggioli, Michela Gentile, Anthea Di Rita, Alessia Noto, Giuseppina Miselli, Fabiana Grazioli, , Stefania Capone

This study evaluates the non-clinical safety of two GRAd vector-based vaccines for COVID-19 and HIV, showing consistent safety profiles and supporting a regulatory platform approach.

Vaccines · Feb 6, 2026Peer-reviewedPharmacology & Toxicology